HEADER HYDROLASE/HYDROLASE INHIBITOR 09-APR-08 2JJJ TITLE ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR. COMPND MOL_ID: 1; COMPND 2 MOLECULE: ENDOTHIAPEPSIN; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: ASPARTATE PROTEASE; COMPND 5 EC: 3.4.23.22; COMPND 6 OTHER_DETAILS: SUCCINAMIDE IS FORMED BETWEEN CHAIN A RESIDUES 54 AND COMPND 7 55.SIMILAR TO PDB 1GKT. SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: CRYPHONECTRIA PARASITICA; SOURCE 3 ORGANISM_COMMON: CHESNUT BLIGHT FUNGUS; SOURCE 4 ORGANISM_TAXID: 5116; SOURCE 5 OTHER_DETAILS: ENDOTHIA PARASITICA FORMULA WEIGHT 33814.2 KEYWDS ACID PROTEINASE, ASPARTYL PROTEASE, ZYMOGEN, HYDROLASE-HYDROLASE KEYWDS 2 INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR L.COATES,H.-F.TUAN,S.J.TOMANICEK,A.KOVALEVSKY,M.MUSTYAKIMOV, AUTHOR 2 P.ERSKINE,J.COOPER REVDAT 9 15-NOV-23 2JJJ 1 REMARK LINK ATOM REVDAT 8 22-MAY-19 2JJJ 1 REMARK LINK REVDAT 7 25-SEP-13 2JJJ 1 REMARK REVDAT 6 13-JUL-11 2JJJ 1 VERSN REVDAT 5 24-FEB-09 2JJJ 1 VERSN REVDAT 4 12-AUG-08 2JJJ 1 JRNL REVDAT 3 15-JUL-08 2JJJ 1 AUTHOR JRNL REMARK REVDAT 2 17-JUN-08 2JJJ 1 JRNL REVDAT 1 27-MAY-08 2JJJ 0 JRNL AUTH L.COATES,H.-F.TUAN,S.J.TOMANICEK,A.KOVALEVSKY,M.MUSTYAKIMOV, JRNL AUTH 2 P.ERSKINE,J.COOPER JRNL TITL THE CATALYTIC MECHANISM OF AN ASPARTIC PROTEINASE EXPLORED JRNL TITL 2 WITH NEUTRON AND X-RAY DIFFRACTION JRNL REF J.AM.CHEM.SOC. V. 130 7235 2008 JRNL REFN ISSN 0002-7863 JRNL PMID 18479128 JRNL DOI 10.1021/JA801269X REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH H.-F.TUAN,P.ERSKINE,P.LANGAN,J.COOPER,L.COATES REMARK 1 TITL PRELIMINARY NEUTRON AND ULTRAHIGH-RESOLUTION X-RAY REMARK 1 TITL 2 DIFFRACTION STUDIES OF THE ASPARTIC PROTEINASE REMARK 1 TITL 3 ENDOTHIAPEPSIN COCRYSTALLIZED WITH A GEM-DIOL INHIBITOR. REMARK 1 REF ACTA CRYSTALLOGR.,SECT.F V. 63 1080 2007 REMARK 1 REFN ESSN 1744-3091 REMARK 1 PMID 18084100 REMARK 1 DOI 10.1107/S1744309107061283 REMARK 2 REMARK 2 RESOLUTION. 1.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 90.8 REMARK 3 CROSS-VALIDATION METHOD : FREE R-VALUE REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.111 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.112 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.136 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.300 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 6783 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 128225 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.111 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.111 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.135 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.300 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 6723 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 126969 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2388 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 74 REMARK 3 SOLVENT ATOMS : 521 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 2974.9 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 2276.0 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 30 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 27648 REMARK 3 NUMBER OF RESTRAINTS : 34213 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.015 REMARK 3 ANGLE DISTANCES (A) : 0.041 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.032 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.090 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.088 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.123 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.005 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.036 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.084 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2JJJ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 09-APR-08. REMARK 100 THE DEPOSITION ID IS D_1290035909. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID29 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 135580 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.000 REMARK 200 RESOLUTION RANGE LOW (A) : 74.320 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.5 REMARK 200 DATA REDUNDANCY : 5.800 REMARK 200 R MERGE (I) : 0.08000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 5.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.05 REMARK 200 COMPLETENESS FOR SHELL (%) : 70.6 REMARK 200 DATA REDUNDANCY IN SHELL : 2.80 REMARK 200 R MERGE FOR SHELL (I) : 0.07000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 10.30 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 37.87 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.67 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 37.17000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OE2 GLU A 47 O HOH A 2099 2.09 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 33 CB - CG - OD2 ANGL. DEV. = -6.1 DEGREES REMARK 500 SUI A 54 CA - C - N ANGL. DEV. = -45.8 DEGREES REMARK 500 VAL A 156 CG1 - CB - CG2 ANGL. DEV. = -11.1 DEGREES REMARK 500 VAL A 156 CA - CB - CG1 ANGL. DEV. = 11.2 DEGREES REMARK 500 ASP A 276 CB - CG - OD1 ANGL. DEV. = -5.8 DEGREES REMARK 500 TYR A 277 CB - CG - CD1 ANGL. DEV. = 4.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2334 DISTANCE = 6.40 ANGSTROMS REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 CHAIN A ENDOTHIAPEPSIN: REMARK 600 RESIDUES ASP 54 AND GLY 55 HAVE CYCLISED REMARK 600 TO FORM A SUCCINIMIDE (RESIDUE SUI 54) REMARK 600 REMARK 600 CHAIN B IN THIS PDB ENTRY IS THE REMARK 600 GEM-DIOL INHIBITOR PD-135.040 REMARK 600 DETAILS: FORMULA WEIGHT 768.0 REMARK 630 REMARK 630 MOLECULE TYPE: PEPTIDE-LIKE INHIBITOR REMARK 630 MOLECULE NAME: N~2~-[(2R)-2-BENZYL-3-(TERT-BUTYLSULFONYL)PROPANOYL] REMARK 630 -N-{(1R)-1-(CYCLOHEXYLMETHYL)-3,3-DIFLUORO-2,2-DIHYDROXY-4-[(2- REMARK 630 MORPHOLIN-4-YLETHYL)AMINO]-4-OXOBUTYL}-3-(1H-IMIDAZOL-3-IUM-4-YL)- REMARK 630 L-ALANINAMIDE REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 0QS A 331 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: TSM PHE HIS CHF EMR REMARK 630 DETAILS: NULL REMARK 700 REMARK 700 SHEET REMARK 700 THE SHEET STRUCTURE OF THIS MOLECULE IS BIFURCATED. IN REMARK 700 ORDER TO REPRESENT THIS FEATURE IN THE SHEET RECORDS BELOW, REMARK 700 TWO SHEETS ARE DEFINED. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 0QS A 331 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 500 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 503 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1GVW RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH PD-130,328 REMARK 900 RELATED ID: 5ER1 RELATED DB: PDB REMARK 900 RELATED ID: 1ENT RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH THE INHIBITOR PD130328 REMARK 900 RELATED ID: 4ER4 RELATED DB: PDB REMARK 900 RELATED ID: 3ER5 RELATED DB: PDB REMARK 900 RELATED ID: 2VS2 RELATED DB: PDB REMARK 900 NEUTRON DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A REMARK 900 GEM-DIOL INHIBITOR. REMARK 900 RELATED ID: 1ER8 RELATED DB: PDB REMARK 900 RELATED ID: 1EPN RELATED DB: PDB REMARK 900 RELATED ID: 1E81 RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA- EMD61395 REMARK 900 RELATED ID: 1E80 RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA- EMD56133 REMARK 900 RELATED ID: 5ER2 RELATED DB: PDB REMARK 900 RELATED ID: 2ER7 RELATED DB: PDB REMARK 900 RELATED ID: 1OD1 RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN PD135,040 COMPLEX REMARK 900 RELATED ID: 1GKT RELATED DB: PDB REMARK 900 NEUTRON LAUE DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH REMARK 900 TRANSITION STATE ANALOGUE INHIBITOR H261 REMARK 900 RELATED ID: 1EPO RELATED DB: PDB REMARK 900 RELATED ID: 1EED RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH THE CYCLOHEXYL RENIN INHIBITOR PD125754 REMARK 900 RELATED ID: 1GVV RELATED DB: PDB REMARK 900 FIVE ATOMIC RESOLUTION STRUCTURES OF ENDOTHIAPEPSIN INHIBITOR REMARK 900 COMPLEXES; IMPLICATIONS FOR THE ASPARTIC PROTEINASE MECHANISM REMARK 900 RELATED ID: 1OEX RELATED DB: PDB REMARK 900 ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A REMARK 900 HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261 REMARK 900 RELATED ID: 2ER0 RELATED DB: PDB REMARK 900 RELATED ID: 1OEW RELATED DB: PDB REMARK 900 ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN REMARK 900 RELATED ID: 2ER9 RELATED DB: PDB REMARK 900 RELATED ID: 1EPP RELATED DB: PDB REMARK 900 RELATED ID: 4APE RELATED DB: PDB REMARK 900 RELATED ID: 2V00 RELATED DB: PDB REMARK 900 X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1 REMARK 900 RELATED ID: 1GVT RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH CP-80,794 REMARK 900 RELATED ID: 1EPL RELATED DB: PDB REMARK 900 RELATED ID: 1EPM RELATED DB: PDB REMARK 900 RELATED ID: 4ER1 RELATED DB: PDB REMARK 900 RELATED ID: 4ER2 RELATED DB: PDB REMARK 900 RELATED ID: 1E82 RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA- EMD59601 REMARK 900 RELATED ID: 1GVX RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEXED WITH H256 REMARK 900 RELATED ID: 2JJI RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR. REMARK 900 RELATED ID: 2ER6 RELATED DB: PDB REMARK 900 RELATED ID: 1E5O RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH INHIBITOR DB2 REMARK 900 RELATED ID: 1GVU RELATED DB: PDB REMARK 900 ENDOTHIAPEPSIN COMPLEX WITH H189 REMARK 900 RELATED ID: 3ER3 RELATED DB: PDB REMARK 900 RELATED ID: 1EPR RELATED DB: PDB REMARK 900 RELATED ID: 1EPQ RELATED DB: PDB DBREF 2JJJ A 1 330 UNP P11838 CARP_CRYPA 90 419 SEQRES 1 A 329 SER THR GLY SER ALA THR THR THR PRO ILE ASP SER LEU SEQRES 2 A 329 ASP ASP ALA TYR ILE THR PRO VAL GLN ILE GLY THR PRO SEQRES 3 A 329 ALA GLN THR LEU ASN LEU ASP PHE ASP THR GLY SER SER SEQRES 4 A 329 ASP LEU TRP VAL PHE SER SER GLU THR THR ALA SER GLU SEQRES 5 A 329 VAL SUI GLN THR ILE TYR THR PRO SER LYS SER THR THR SEQRES 6 A 329 ALA LYS LEU LEU SER GLY ALA THR TRP SER ILE SER TYR SEQRES 7 A 329 GLY ASP GLY SER SER SER SER GLY ASP VAL TYR THR ASP SEQRES 8 A 329 THR VAL SER VAL GLY GLY LEU THR VAL THR GLY GLN ALA SEQRES 9 A 329 VAL GLU SER ALA LYS LYS VAL SER SER SER PHE THR GLU SEQRES 10 A 329 ASP SER THR ILE ASP GLY LEU LEU GLY LEU ALA PHE SER SEQRES 11 A 329 THR LEU ASN THR VAL SER PRO THR GLN GLN LYS THR PHE SEQRES 12 A 329 PHE ASP ASN ALA LYS ALA SER LEU ASP SER PRO VAL PHE SEQRES 13 A 329 THR ALA ASP LEU GLY TYR HIS ALA PRO GLY THR TYR ASN SEQRES 14 A 329 PHE GLY PHE ILE ASP THR THR ALA TYR THR GLY SER ILE SEQRES 15 A 329 THR TYR THR ALA VAL SER THR LYS GLN GLY PHE TRP GLU SEQRES 16 A 329 TRP THR SER THR GLY TYR ALA VAL GLY SER GLY THR PHE SEQRES 17 A 329 LYS SER THR SER ILE ASP GLY ILE ALA ASP THR GLY THR SEQRES 18 A 329 THR LEU LEU TYR LEU PRO ALA THR VAL VAL SER ALA TYR SEQRES 19 A 329 TRP ALA GLN VAL SER GLY ALA LYS SER SER SER SER VAL SEQRES 20 A 329 GLY GLY TYR VAL PHE PRO CYS SER ALA THR LEU PRO SER SEQRES 21 A 329 PHE THR PHE GLY VAL GLY SER ALA ARG ILE VAL ILE PRO SEQRES 22 A 329 GLY ASP TYR ILE ASP PHE GLY PRO ILE SER THR GLY SER SEQRES 23 A 329 SER SER CYS PHE GLY GLY ILE GLN SER SER ALA GLY ILE SEQRES 24 A 329 GLY ILE ASN ILE PHE GLY ASP VAL ALA LEU LYS ALA ALA SEQRES 25 A 329 PHE VAL VAL PHE ASN GLY ALA THR THR PRO THR LEU GLY SEQRES 26 A 329 PHE ALA SER LYS MODRES 2JJJ SUI A 54 ASP MODRES 2JJJ SUI A 54 GLY HET SUI A 54 11 HET 0QS A 331 61 HET SO4 A 500 5 HET SO4 A 501 5 HET SO4 A 502 5 HET SO4 A 503 5 HETNAM SUI (3-AMINO-2,5-DIOXO-1-PYRROLIDINYL)ACETIC ACID HETNAM 0QS N~2~-[(2R)-2-BENZYL-3-(TERT-BUTYLSULFONYL)PROPANOYL]-N- HETNAM 2 0QS {(1R)-1-(CYCLOHEXYLMETHYL)-3,3-DIFLUORO-2,2-DIHYDROXY- HETNAM 3 0QS 4-[(2-MORPHOLIN-4-YLETHYL)AMINO]-4-OXOBUTYL}-3-(1H- HETNAM 4 0QS IMIDAZOL-3-IUM-4-YL)-L-ALANINAMIDE HETNAM SO4 SULFATE ION HETSYN 0QS PD-135,040 FORMUL 1 SUI C6 H8 N2 O4 FORMUL 2 0QS C36 H56 F2 N7 O8 S 1+ FORMUL 3 SO4 4(O4 S 2-) FORMUL 7 HOH *521(H2 O) HELIX 1 1 THR A 49 VAL A 53 5 5 HELIX 2 2 THR A 60 SER A 64 5 5 HELIX 3 3 SER A 113 ASP A 119 1 7 HELIX 4 4 PHE A 130 ASN A 134 5 5 HELIX 5 5 THR A 143 LYS A 149 1 7 HELIX 6 6 PRO A 228 ALA A 237 1 10 HELIX 7 7 PRO A 274 TYR A 277 5 4 HELIX 8 8 GLY A 306 LYS A 311 1 6 SHEET 1 AA 3 LYS A 68 SER A 78 0 SHEET 2 AA 3 SER A 84 VAL A 96 -1 O SER A 85 N ILE A 77 SHEET 3 AA 3 TYR A 17 ILE A 23 -1 O GLN A 22 N SER A 95 SHEET 1 AB 7 LYS A 68 SER A 78 0 SHEET 2 AB 7 SER A 84 VAL A 96 -1 O SER A 85 N ILE A 77 SHEET 3 AB 7 LEU A 99 VAL A 112 -1 O LEU A 99 N VAL A 96 SHEET 4 AB 7 LEU A 41 VAL A 43 1 O LEU A 41 N GLU A 107 SHEET 5 AB 7 GLY A 124 GLY A 127 -1 O LEU A 125 N TRP A 42 SHEET 6 AB 7 GLN A 28 ASP A 35 1 O ASP A 33 N LEU A 126 SHEET 7 AB 7 TYR A 17 ILE A 23 -1 O THR A 19 N LEU A 32 SHEET 1 AC 5 GLU A 196 SER A 199 0 SHEET 2 AC 5 ILE A 214 ALA A 218 -1 O ILE A 214 N SER A 199 SHEET 3 AC 5 ASN A 303 PHE A 305 1 O ASN A 303 N ILE A 217 SHEET 4 AC 5 LEU A 225 LEU A 227 -1 O TYR A 226 N ILE A 304 SHEET 5 AC 5 ILE A 294 SER A 296 1 O GLN A 295 N LEU A 227 SHEET 1 AD 3 TYR A 202 VAL A 204 0 SHEET 2 AD 3 PHE A 262 VAL A 266 -1 O THR A 263 N ALA A 203 SHEET 3 AD 3 ALA A 269 ILE A 273 -1 O ALA A 269 N VAL A 266 SHEET 1 AE 4 LYS A 243 SER A 245 0 SHEET 2 AE 4 GLY A 250 PRO A 254 -1 O GLY A 250 N SER A 245 SHEET 3 AE 4 SER A 289 GLY A 292 -1 O CYS A 290 N PHE A 253 SHEET 4 AE 4 ASP A 279 PRO A 282 -1 N PHE A 280 O PHE A 291 SSBOND 1 CYS A 255 CYS A 290 1555 1555 2.05 LINK C VAL A 53 N SUI A 54 1555 1555 1.31 LINK C SUI A 54 N GLN A 56 1555 1555 1.33 CISPEP 1 THR A 25 PRO A 26 0 -8.90 CISPEP 2 SER A 137 PRO A 138 0 6.82 CISPEP 3 SER A 137 PRO A 138 0 8.41 SITE 1 AC1 23 ASP A 15 ASP A 33 ASP A 35 GLY A 37 SITE 2 AC1 23 SER A 38 TYR A 79 GLY A 80 ASP A 81 SITE 3 AC1 23 SER A 83 PHE A 116 ASP A 119 LEU A 133 SITE 4 AC1 23 ASP A 219 GLY A 221 THR A 222 THR A 223 SITE 5 AC1 23 ILE A 300 ILE A 304 HOH A2260 HOH A2398 SITE 6 AC1 23 HOH A2518 HOH A2519 HOH A2520 SITE 1 AC2 10 SER A 113 SER A 114 THR A 321 THR A 322 SITE 2 AC2 10 SO4 A 503 HOH A2237 HOH A2507 HOH A2508 SITE 3 AC2 10 HOH A2509 HOH A2510 SITE 1 AC3 4 LYS A 68 LEU A 69 HOH A2511 HOH A2512 SITE 1 AC4 3 LYS A 191 HOH A2513 HOH A2515 SITE 1 AC5 9 ASP A 81 GLY A 82 SER A 83 SER A 113 SITE 2 AC5 9 SER A 114 SER A 115 SO4 A 500 HOH A2516 SITE 3 AC5 9 HOH A2517 CRYST1 42.690 74.340 42.530 90.00 97.49 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023425 0.000000 0.003080 0.00000 SCALE2 0.000000 0.013452 0.000000 0.00000 SCALE3 0.000000 0.000000 0.023715 0.00000